Valuation: Bicycle Therapeutics plc

Market Cap 236M 214M 198M 179M 337M 22.27B 349M 2.38B 943M 11.9B 886M 868M 37.77B P/E 2026 *
-1.49x
P/E 2027 * -1.43x
Enterprise Value -246M -223M -206M -186M -351M -23.21B -363M -2.48B -983M -12.4B -924M -904M -39.36B EV / Sales 2026 *
-6.54x
EV / Sales 2027 * -21x
Free-Float
71.15%
Yield 2026 *
-
Yield 2027 * -
1 day-2.32%
1 week-6.65%
Current month-7.92%
1 month-6.39%
3 months-13.59%
6 months-24.27%
Current year-52.40%
1 week 3.26
Extreme 3.26
3.78
1 month 3.26
Extreme 3.26
4.14
Current year 3.26
Extreme 3.26
7.34
1 year 3.26
Extreme 3.26
7.83
3 years 3.26
Extreme 3.26
28.67
5 years 3.26
Extreme 3.26
61.5
10 years 3.26
Extreme 3.26
62.08
Manager TitleAgeSince
Chief Executive Officer 57 2015-08-31
Director of Finance/CFO 46 2026-01-28
Chief Tech/Sci/R&D Officer - 2025-05-31
Director TitleAgeSince
Director/Board Member 57 2015-08-31
Director/Board Member 63 2021-03-16
Director/Board Member 69 2024-02-19
Date Insider Type Main position Quantity % Market Cap. Importance
10/5/26 Sell

Chief Operating Officer

-356 0.0009%
10/5/26 Sell

Chief Operating Officer

-406 0.0011%
10/5/26 Sell

Chief Financial Officer

-79 0.0002%
Change 5-day change 1-year change 3-year change Capi.($)
-2.32%-6.65%-47.99%-78.10% 236M
-2.69%-0.48%+53.97%+66.82% 66.33B
+0.16%+3.05%+11.03%+95.51% 60.62B
+0.89%+1.79%+24.43%+89.98% 55.5B
+0.14%+2.35%+13.86%+111.94% 47.58B
-2.21%-2.47%+20.18%+28.81% 43.69B
-2.30%-10.40%+154.30%+707.36% 37.27B
+2.15%+1.42%+14.58%+48.71% 36.57B
+2.35%-3.69%+78.49%+60.56% 32.22B
+2.62%+5.90%-37.29%+386.59% 26.58B
Average -0.13%-0.62%+28.56%+151.82% 41B
Weighted average by Cap. -0.19%+0.20%+36.78%+152.86%

Financials

2026 *2027 *
Net sales 37.65M 34.12M 31.56M 28.47M 53.65M 3.55B 55.54M 379M 150M 1.9B 141M 138M 6.02B 5.28M 4.79M 4.43M 3.99M 7.53M 498M 7.79M 53.17M 21.08M 266M 19.82M 19.4M 844M
Net income -159M -144M -133M -120M -226M -14.95B -234M -1.6B -633M -7.99B -595M -583M -25.36B -179M -162M -150M -135M -255M -16.88B -264M -1.8B -715M -9.02B -672M -657M -28.62B
Net Debt -482M -437M -404M -365M -688M -45.48B -712M -4.86B -1.93B -24.3B -1.81B -1.77B -77.13B -347M -315M -291M -263M -495M -32.74B -512M -3.5B -1.39B -17.49B -1.3B -1.28B -55.52B
Projected Income Statement - Annual - Bicycle Therapeutics plc
Logo Bicycle Therapeutics plc
Bicycle Therapeutics plc is a United Kingdom-based clinical-stage biopharmaceutical company developing a class of medicines, referred to as Bicycle molecules, for diseases that are underserved by existing therapeutics. Bicycle molecules are fully synthetic short peptides constrained with small molecule scaffolds to form two loops that stabilize their structural geometry. The Company is evaluating zelenectide pevedotin, a Bicycle Toxin Conjugate (BTC) targeting Nectin-4, a well-validated tumor antigen; BT5528, a BTC targeting EphA2, a historically undruggable target, and BT7480, a Bicycle Tumor-Targeted Immune Cell Agonist (Bicycle TICA) targeting Nectin-4 and agonizing CD137, in Company-sponsored clinical trials. Additionally, the Company is developing Bicycle Radio Conjugates (BRC) for radiopharmaceutical use and, through various partnerships, is exploring the use of Bicycle technology to develop therapies for diseases beyond oncology.
Employees
288
Date Price Change Volume
26-11-13 $3.370 -2.32% 604,366
26-11-12 $3.450 -6.50% 630,101
26-11-11 $3.690 0.00% 171,799
26-11-10 $3.690 -2.12% 234,734
26-11-09 $3.770 +4.43% 590,289
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
MarketScreener Ratings - Bicycle Therapeutics plc
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
9
Last Close Price
3.370USD
Average target price
9.167USD
Spread / Average Target
+172.01%
  1. Stock Market
  2. Stocks
  3. BCYC Stock